<code id='FA02837E7F'></code><style id='FA02837E7F'></style>
    • <acronym id='FA02837E7F'></acronym>
      <center id='FA02837E7F'><center id='FA02837E7F'><tfoot id='FA02837E7F'></tfoot></center><abbr id='FA02837E7F'><dir id='FA02837E7F'><tfoot id='FA02837E7F'></tfoot><noframes id='FA02837E7F'>

    • <optgroup id='FA02837E7F'><strike id='FA02837E7F'><sup id='FA02837E7F'></sup></strike><code id='FA02837E7F'></code></optgroup>
        1. <b id='FA02837E7F'><label id='FA02837E7F'><select id='FA02837E7F'><dt id='FA02837E7F'><span id='FA02837E7F'></span></dt></select></label></b><u id='FA02837E7F'></u>
          <i id='FA02837E7F'><strike id='FA02837E7F'><tt id='FA02837E7F'><pre id='FA02837E7F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:hotspot    - browse:979
          Rachel Haurwitz of Caribou Biosciences
          Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

          Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

          In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

          advertisement

          The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          entertainment